August 19, 2019 A new study led by Dr. S. Sam Lim of Emory University found a need for more awareness of biologic therapies among both black and white people with lupus. Biologics are medicines that come from living cells to prevent, treat and cure human diseases, and are designed to have specific effects on […] READ MORE
August 15, 2019 While August is when we savor the last weeks of summer, it is also the time to look ahead and prepare for fall. In recognition of National Immunization Month, our Chief Scientific Officer Dr. Teodora Staeva provides background on vaccines and relays government recommendations for which are safe for people with lupus. […] READ MORE
August 13, 2019 New research results showed that active Epstein-Barr virus increases the risk for lupus among relatives of people who already have lupus. Epstein-Barr virus is one of the most common human viruses. After the first infection, the virus becomes inactive in your body and can reactivate at any time. Scientists have known that […] READ MORE
August 12, 2019 A specific antibody target has been identified as causing neuropsychiatric symptoms of lupus, according to a study at SUNY Downstate Health Sciences University published in the Journal of Neuroscience. These common symptoms include cognitive impairment, meaning that the person has trouble thinking, learning or remembering. Other symptoms include mood changes, seizures, headaches […] READ MORE
August 12, 2019 Bacteremia, bacteria in the bloodstream, is associated with severe lupus flares and corticosteroid use, according to a new study published in The Journal of Rheumatology. Conducted in Spain, the study looked at all cases of bacteremia included in a national registry of hospitalized patients. It contains data from 3,679 lupus patients at […] READ MORE
August 8, 2019 All of us here at LRA congratulate Daemion T. Johnson – GSK’s Director, Patient Engagement. He was named one of the PharmaVOICE 100 by the magazine PharmaVOICE.com. This list recognizes 100 men and women in the life-sciences industry who “provide inspiration to their peers, colleagues, and companies through their innovative and motivational […] READ MORE
August 7, 2019 Dr. Chandra Mohan discovered that blood clotting proteins are higher in the urine of people with lupus nephritis, announced University of Houston. His work showed that both proteins that promote clotting and those that work to dissolve them are involved. He began examining these proteins because people with lupus and lupus nephritis […] READ MORE
August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […] READ MORE
August 5, 2019 A new study conducted at Hospital for Special Surgery (HSS) showed that the PROMIS® (Patient-Related Outcomes Measurement Information System) health survey can be used to measure and monitor patients’ experience of lupus that are not captured by standard questionnaires. Researchers gave 223 people with lupus who get their outpatient care at HSS […] READ MORE
August 1, 2019 A new study by LRA Distinguished Innovator Award recipient Dr. Douglas Green of St. Jude Children’s Research Hospital in Memphis, TN, and colleagues may have uncovered a new way to treat Alzheimer’s disease. The research, highlighted recently in Forbes magazine and published in the journal Cell, identified one of the brain’s mechanisms […] READ MORE
August 1, 2019 The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, is very pleased to announce a unique new partnership with Celgene Corporation that provides $3,000,000 for bold cutting-edge research projects. This opportunity will focus on understanding the underlying mechanisms of disease, addressing lupus heterogeneity — how much […] READ MORE
July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132. Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […] READ MORE
